← Product Code [LZO](/submissions/OR/subpart-d%E2%80%94prosthetic-devices/LZO) · K231109 # Xerxes Hip Stem (K231109) _Xerxes Arthopedix, LLC · LZO · Jun 15, 2023 · Orthopedic · SESE_ **Canonical URL:** https://fda.innolitics.com/submissions/OR/subpart-d%E2%80%94prosthetic-devices/LZO/K231109 ## Device Facts - **Applicant:** Xerxes Arthopedix, LLC - **Product Code:** [LZO](/submissions/OR/subpart-d%E2%80%94prosthetic-devices/LZO.md) - **Decision Date:** Jun 15, 2023 - **Decision:** SESE - **Submission Type:** Traditional - **Regulation:** 21 CFR 888.3353 - **Device Class:** Class 2 - **Review Panel:** Orthopedic - **Attributes:** Therapeutic ## Intended Use Xerxes Hip Stems, when used with cleared and compatible Signature Orthopaedics hip replacement components, are intended to replace a hip joint where bone stock is sufficient to support the implant. When a surgeon has selected prosthetic replacement as the preferred treatment, the devices are indicated for: - Non-inflammatory degenerative joint disease including osteoarthritis or avascular necrosis - Inflammatorv joint disease including rheumatoid arthritis - Correction of functional deformity including congenital hip dysplasia - Traumatic injury involving the hip joint including traumatic arthritis or femoral head or neck fracture - Failed previous hip surgery including internal fixation or joint fusion, reconstruction, hemiarthroplasty, surface replacement, or total replacement. Xerxes Hip femoral stems are intended for cementless fixation only. The Xerxes Hip System is intended for use with Logical, World Acetabular System and Signature Orthopaedics' Femoral Heads. Xerxes Hip when used with constrained liner components is indicated particularly for patients at high risk of hip dislocation due to history of prior dislocation, bone loss, joint or soft tissue laxity, neuromuscular disease, or intraoperative instability. ## Device Story Xerxes Hip Stem is a cementless femoral component for total hip arthroplasty; used in conjunction with compatible acetabular shells and femoral heads. Device features anatomical stem with 5° anteversion neck and 250 mm radius curvature. Surface treatment includes distal color-anodized polished tip; middle section with hydroxyapatite coating; proximal section with titanium plasma spray. Implanted by orthopedic surgeons in clinical/hospital settings to replace diseased or damaged hip joints. Provides structural support for hip joint; restores function; reduces pain. Output is physical prosthetic replacement; clinical decision-making based on surgeon assessment of bone stock and patient risk factors. ## Clinical Evidence Bench testing only. No clinical or animal data required. Testing included range of motion (ISO 21535), stem and neck fatigue (ISO 7206-4, ISO 7206-6), FEA (ASTM F2996), and pyrogenicity/endotoxin testing (AAMI ST72). ## Technological Characteristics Forged titanium alloy (Ti6Al4V) per ISO 5832-3/ASTM F136. Hydroxyapatite coating per ISO 13779-2; titanium plasma spray per ASTM F1580. 12/14 femoral head connection. Cementless fixation. Sterilized using methods consistent with predicate devices. ## Regulatory Identification A hip joint metal/ceramic/polymer semi-constrained cemented or nonporous uncemented prosthesis is a device intended to be implanted to replace a hip joint. This device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across-the-joint. The two-part femoral component consists of a femoral stem made of alloys to be fixed in the intramedullary canal of the femur by impaction with or without use of bone cement. The proximal end of the femoral stem is tapered with a surface that ensures positive locking with the spherical ceramic (aluminium oxide, A12 03 ) head of the femoral component. The acetabular component is made of ultra-high molecular weight polyethylene or ultra-high molecular weight polyethylene reinforced with nonporous metal alloys, and used with or without bone cement. ## Predicate Devices - Medacta International's MiniMAX Stem ([K170845](/device/K170845.md) & [K192352](/device/K192352.md)) - Signature Orthopaedics' Spartan Hip Stem ([K192883](/device/K192883.md)) - Signature Orthopaedics' Everglade Hip Stem ([K211505](/device/K211505.md)) - Signature Orthopaedics' OriginTM Total Hip System ([K121297](/device/K121297.md)) - Signature Orthopaedics' Logical C-Series Acetabular Shell, Logical Constrained Liner, Logical Constrained Liner Collar, Logical 20° Hooded Acetabular Liner ([K153131](/device/K153131.md)) ## Submission Summary (Full Text) > This content was OCRed from public FDA records by [Innolitics](https://innolitics.com). If you use, quote, summarize, crawl, or train on this content, cite Innolitics at https://innolitics.com. > > Innolitics is a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices, including [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/). {0}------------------------------------------------ Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: a symbol on the left and the FDA name and title on the right. The symbol on the left is a stylized representation of a human figure, while the text on the right reads "FDA U.S. FOOD & DRUG ADMINISTRATION" in blue letters. June 15, 2023 Xerxes Arthopedix LLC H Kurtis Biggs President 181 Eugenia Dr. Naples, Florida 34108 Re: K231109 Trade/Device Name: Xerxes Hip Stem Regulation Number: 21 CFR 888.3353 Regulation Name: Hip Joint Metal/Ceramic/Polymer Semi-Constrained Cemented Or Nonporous Uncemented Prosthesis Regulatory Class: Class II Product Code: LZO, MEH, KWZ Dated: April 13, 2023 Received: April 19, 2023 Dear Dr. H Kurtis Biggs: We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. {1}------------------------------------------------ Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems. For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100). Sincerely. # Limin Sun -S Limin Sun, Ph.D. Assistant Director DHT6A: Division of Joint Arthroplasty Devices OHT6: Office of Orthopedic Devices Office of Product Evaluation and Ouality Center for Devices and Radiological Health Enclosure {2}------------------------------------------------ # Indications for Use 510(k) Number (if known) K231109 Device Name Xerxes Hip Stem #### Indications for Use (Describe) Xerxes Hip Stems, when used with cleared and compatible Signature Orthopaedics hip replacement components, are intended to replace a hip joint where bone stock is sufficient to support the implant. When a surgeon has selected prosthetic replacement as the preferred treatment, the devices are indicated for: - Non-inflammatory degenerative joint disease including osteoarthritis or avascular necrosis - Inflammatorv joint disease including rheumatoid arthritis - Correction of functional deformity including congenital hip dysplasia - Traumatic injury involving the hip joint including traumatic arthritis or femoral head or neck fracture - Failed previous hip surgery including internal fixation or joint fusion, reconstruction, hemiarthroplasty, surface replacement, or total replacement. Xerxes Hip femoral stems are intended for cementless fixation only. The Xerxes Hip System is intended for use with Logical, World Acetabular System and Signature Orthopaedics' Femoral Heads. Xerxes Hip when used with constrained liner components is indicated particularly for patients at high risk of hip dislocation due to history of prior dislocation, bone loss, joint or soft tissue laxity, neuromuscular disease, or intraoperative instability. Type of Use (Select one or both, as applicable) | Prescription Use (Part 21 CFR 801 Subpart D) | ✔ | |----------------------------------------------|-----------------------------------------------------| | Over-The-Counter Use (21 CFR 801 Subpart C) | □ | #### CONTINUE ON A SEPARATE PAGE IF NEEDED. This section applies only to requirements of the Paperwork Reduction Act of 1995. #### *DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.* The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to: > Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov "An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number." {3}------------------------------------------------ ## 510(K) SUMMARY | Device Trade Name: | Xerxes Hip Stem | |--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | Common Name: | Cementless Hip Replacement Prosthesis | | Contact: | Dr. H. Kurtis Biggs
President, Xerxes Arthropedix LLC | | Submitter: | Xerxes Arthropedix LLC
181 Eugenia Dr., Naples, FL 34108
Phone: 239-313-0543
Fax: 239-262-5633 | | Date Prepared: | 15 June 2023 | | Classification: | Class II as per 21 CFR 888.3353 Hip joint metal/ceramic/polymer
semi-constrained cemented or nonporous uncemented prosthesis
Class II as per 21 CFR 888.3310 Hip joint metal/polymer
constrained cemented or uncemented prosthesis | | Product Codes: | LZO, MEH, KWZ | | Predicate Devices: | Primary Predicate Medacta International's MiniMAX Stem (K170845 & K192352) Additional Predicate Device(s): Signature Orthopaedics' Spartan Hip Stem (K192883) Signature Orthopaedics' Everglade Hip Stem (K211505) Signature Orthopaedics' OriginTM Total Hip System (K121297) Signature Orthopaedics' Logical C-Series Acetabular Shell, Logical Constrained Liner, Logical Constrained Liner Collar, Logical 20° Hooded Acetabular Liner (K153131) | #### Device Description: Xerxes™ Hip Stem is manufactured from forged titanium alloy (Ti6Al4V) as per ISO 5832-3 and ASTM F136. The Xerxes™ Hip Stem is an anatomical stem with a 5° anteversion neck and a 250 mm radius curvature on the stem body. The stem has three different surface and/or coating areas. The distal tip portion is colour anodised, polished, and rounded to aid in the insertion and avoiding distal interference. The remainder of the stem below its resection line is coated for cementless fixation. The middle portion of the stem is coated with a single layer of hydroxyapatite coating, as per ISO 13779-2 while the proximal portion is coated with an additional layer of titanium plasma spray as per ASTM F1580. #### Indications for Use: Xerxes M Hip Stems, when used with cleared and compatible Signature Orthopaedics hip replacement components, are intended to replace a hip joint where bone stock is sufficient to {4}------------------------------------------------ support the implant. When a surgeon has selected prosthetic replacement as the preferred treatment, the devices are indicated for: - . Non-inflammatory degenerative joint disease including osteoarthritis or avascular necrosis - Inflammatory joint disease including rheumatoid arthritis - Correction of functional deformity including congenital hip dysplasia - Traumatic injury involving the hip joint including traumatic arthritis or femoral head or . neck fracture - Failed previous hip surgery including internal fixation or joint fusion, reconstruction, . hemiarthroplasty, surface replacement, or total replacement Xerxes™ Hip femoral stems are intended for cementless fixation only. The Xerxes™ Hip System is intended for use with Logical™, World™ Acetabular Systems and Signature Orthopaedics' Femoral Heads. Xerxes™ Hip when used with constrained liner components is indicated particularly for patients at high risk of hip dislocation due to a history of prior dislocation, bone loss, joint or soft tissue laxity, neuromuscular disease, or intraoperative instability. ## Summary of Technological Characteristics: Hip arthroplasty is the technological principle for both the subject and the predicate devices. The subject and primary predicate devices are based on the same technological elements as listed below: - The subject device is intended for cementless fixation which is the same intended use ● as the MiniMAX Stem. - The indications for use of the subject device are the same as the MiniMAX Stem. ● - . The intended surgery sites of the subject device match the intended surgery sites of the MiniMAX Stem. - . The subject devices are manufactured from the same raw and coating materials as the MiniMAX Stem. - . The subject device has the same design features and size ranges as Medacta International's MiniMAX Stem. - . The subject device has the same 12/14 femoral head connection feature as the MiniMax Stem The following are the technological differences between the subject device and the primary predicate devices: - The subject device has a smaller anteversion angle neck design than the MiniMAX ● Stem Further comparison of the subject device and additional predicate devices was made and found that: - . The subject device has the same 12/14 trunnion geometry as the Spartan and Everglade Stems. - . The subject device has the same surface finish on the taper connection as the Spartan and Everglade Stems. - The subject device is compatible with the same femoral heads and associated acetabular components as the Spartan and Everglade Hip Stems. - . The subject device is manufactured and sterilised using the same methods as the Spartan and Everglade Stems. {5}------------------------------------------------ ## Performance Data: Non-clinical testing and engineering evaluations were conducted to verify that the performance of the Xerxes Hip Stem is adequate for anticipated in-vivo use. No animal or clinical testing was required to support substantial equivalence. Non-clinical testing carried out included: - . Range of Motion testing as per ISO 21535 - Stem and Neck Fatigue FEA as per ASTM F2996 ● - Stem and Neck Fatigue Testing as per ISO 7206-4 and ISO 7206-6 . - . Pyrogenicity and Endotoxin Testing as per AAMI ST72 #### Conclusion: Xerxes™ Stem is substantially equivalent to Medacta International's MiniMAX Stem (K170845 and K192352) since it has the same intended use, indications for use, material and similar design features. Non-clinical testing results support the substantial equivalence claim. Therefore, the subject devices are expected to perform adequately during clinical use. --- **Source:** [https://fda.innolitics.com/submissions/OR/subpart-d%E2%80%94prosthetic-devices/LZO/K231109](https://fda.innolitics.com/submissions/OR/subpart-d%E2%80%94prosthetic-devices/LZO/K231109) **Published by [Innolitics](https://innolitics.com)** — a medical-device software consultancy. We help companies design, build, and clear FDA-regulated software and AI/ML devices. If you're preparing [a 510(k)](https://innolitics.com/services/510ks/), [a De Novo](https://innolitics.com/services/regulatory/), [a SaMD](https://innolitics.com/services/end-to-end-samd/), [an AI/ML medical device](https://innolitics.com/services/medical-imaging-ai-development/), or [an FDA regulatory strategy](https://innolitics.com/services/regulatory/), [get in touch](https://innolitics.com/contact). **Cite:** Innolitics at https://innolitics.com